Gamma-aminobutyric acid type A receptor subunit alpha1 (GABRA1)

GABRA1-containing GABA-A receptors are the most abundant subtype of ionotropic gamma-aminobutyric acid (GABA) receptors in the mammalian brain, typically existing as pentameric complexes of alpha-1, beta, and gamma subunits (Source [6], [13]). These receptors function as ligand-gated chloride channels that mediate fast inhibitory synaptic transmission; upon GABA binding, the channel opens to allow chloride influx, hyperpolarizing the neuron and reducing its excitability (Source [1], [9]). The alpha-1 subunit is a primary target for several classes of clinically important drugs, including benzodiazepines, barbiturates, and "Z-drugs" like zolpidem, which enhance receptor activity to produce sedative, anticonvulsant, and anxiolytic effects (Source [4], [15]). Mutations in the GABRA1 gene are a well-established cause of genetic epilepsies, such as juvenile myoclonic epilepsy and childhood absence epilepsy, often resulting from reduced receptor surface expression or impaired channel gating (Source [11], [12]). Additionally, dysregulation of these receptors is implicated in the pathophysiology of schizophrenia, autism spectrum disorders, and chronic insomnia (Source [4], [10]). Understanding the specific role of the alpha-1 subunit is crucial for developing subtype-selective therapies that aim to minimize side effects like sedation and cognitive impairment associated with broad-spectrum GABAergic modulation (Source [8], [9]).

Other names

Gamma-aminobutyric acid receptor subunit alpha-1GABA(A) receptor subunit alpha-1GABAAR subunit alpha-1EJM5ECA4EIEE19DEE19

Positive allosteric modulation of the GABA-A receptor, which increases the frequency or duration of chloride channel opening in response to GABA binding, thereby enhancing inhibitory neurotransmission (Source [7], [9]).